

# Liza-Marie Johnson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5805542/publications.pdf>

Version: 2024-02-01

72  
papers

880  
citations

430874

18  
h-index

526287

27  
g-index

74  
all docs

74  
docs citations

74  
times ranked

993  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomes for Kids: The Scope of Pathogenic Mutations in Pediatric Cancer Revealed by Comprehensive DNA and RNA Sequencing. <i>Cancer Discovery</i> , 2021, 11, 3008-3027.	9.4	88
2	Pediatric Palliative Sedation Therapy with Propofol: Recommendations Based on Experience in Children with Terminal Cancer. <i>Journal of Palliative Medicine</i> , 2012, 15, 1082-1090.	1.1	58
3	Integrating next-generation sequencing into pediatric oncology practice: An assessment of physician confidence and understanding of clinical genomics. <i>Cancer</i> , 2017, 123, 2352-2359.	4.1	58
4	Ethics Consultation in Pediatrics: Long-Term Experience From a Pediatric Oncology Center. <i>American Journal of Bioethics</i> , 2015, 15, 3-17.	0.9	57
5	Illness and end-of-life experiences of children with cancer who receive palliative care. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26895.	1.5	53
6	Predictors of Late Palliative Care Referral in Children With Cancer. <i>Journal of Pain and Symptom Management</i> , 2018, 55, 1550-1556.	1.2	36
7	Integrating Palliative Care in Pediatric Oncology: Evidence for an Evolving Paradigm for Comprehensive Cancer Care. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 741-748.	4.9	35
8	Practical communication guidance to improve phase 1 informed consent conversations and decision-making in pediatric oncology. <i>Cancer</i> , 2015, 121, 2439-2448.	4.1	34
9	Does phase 1 trial enrollment preclude quality end-of-life care? Phase 1 trial enrollment and end-of-life care characteristics in children with cancer. <i>Cancer</i> , 2015, 121, 1508-1512.	4.1	34
10	End-of-Life Care for Hospitalized Children. <i>Pediatric Clinics of North America</i> , 2014, 61, 835-854.	1.8	32
11	Speaking genomics to parents offered germline testing for cancer predisposition: Use of a 2-visit consent model. <i>Cancer</i> , 2019, 125, 2455-2464.	4.1	29
12	Chemotherapy and Supportive Care Agents as Essential Medicines for Children With Cancer. <i>JAMA Pediatrics</i> , 2019, 173, 477.	6.2	28
13	Are we meeting the informational needs of cancer patients and families? Perception of physician communication in pediatric oncology. <i>Cancer</i> , 2019, 125, 1518-1526.	4.1	28
14	Predictors of Location of Death for Children with Cancer Enrolled on a Palliative Care Service. <i>Oncologist</i> , 2018, 23, 1525-1532.	3.7	27
15	Impact of Race and Ethnicity on End-of-Life Experiences for Children With Cancer. <i>American Journal of Hospice and Palliative Medicine</i> , 2019, 36, 767-774.	1.4	26
16	Ethical considerations surrounding germline next-generation sequencing of children with cancer. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 523-534.	3.1	23
17	Ethical issues in the care of adolescent and young adult oncology patients. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27608.	1.5	22
18	Palliative Sedation With Propofol for an Adolescent With a DNR Order. <i>Pediatrics</i> , 2017, 140, .	2.1	20

#	ARTICLE	IF	CITATIONS
19	Factors Associated With Declining to Participate in a Pediatric Oncology Next-Generation Sequencing Study. <i>JCO Precision Oncology</i> , 2020, 4, 202-211.	3.0	15
20	Management of Concurrent Pregnancy and Acute Lymphoblastic Malignancy in Teenaged Patients: Two Illustrative Cases and Review of the Literature. <i>Journal of Adolescent and Young Adult Oncology</i> , 2014, 3, 160-175.	1.3	13
21	The role of the pediatric anesthesiologist in relieving suffering at the end of life: when is palliative sedation appropriate in pediatrics?. <i>Paediatric Anaesthesia</i> , 2017, 27, 443-444.	1.1	11
22	The bereavement experience of adolescents and early young adults with cancer: Peer and parental loss due to death is associated with increased risk of adverse psychological outcomes. <i>PLoS ONE</i> , 2017, 12, e0181024.	2.5	11
23	Knowledge Is Power: Benefits, Risks, Hopes, and Decision-Making Reported by Parents Consenting to Next-Generation Sequencing for Children and Adolescents with Cancer. <i>Seminars in Oncology Nursing</i> , 2021, 37, 151167.	1.5	11
24	Recruiting Children for Clinical Trials: Lessons From Pediatric Oncology. <i>American Journal of Bioethics</i> , 2015, 15, 24-26.	0.9	9
25	Should Poor Social Support Be an Exclusion Criterion in Bone Marrow Transplantation?. <i>American Journal of Bioethics</i> , 2019, 19, 39-41.	0.9	8
26	Ethical Decision Making About End-of-life Care Issues by Pediatric Oncologists in Economically Diverse Settings. <i>Journal of Pediatric Hematology/Oncology</i> , 2015, 37, 257-263.	0.6	7
27	Managing Pandora's Box: Familial Expectations around the Return of (Future) Germline Results. <i>AJOB Empirical Bioethics</i> , 2022, 13, 152-165.	1.6	7
28	Beyond Parenting: The Responsibility of Multidisciplinary Health Care Providers in Early Intervention Policy Guidance. <i>American Journal of Bioethics</i> , 2018, 18, 58-60.	0.9	6
29	An Unusual Case of Ogilvie Syndrome in a Pediatric Oncology Patient Receiving Palliative Care after Failed Treatment with Neostigmine. <i>Journal of Palliative Medicine</i> , 2012, 15, 1042-1046.	1.1	5
30	Mitigating Challenges in Dual-Role Consent: Honoring Patient Preferences to Discuss Research Participation With Someone They Know. <i>American Journal of Bioethics</i> , 2019, 19, 30-32.	0.9	5
31	Outcomes and Disposition of Oncology Patients With Non-neutropenic Fever and Positive Blood Cultures. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, 43, 47-51.	0.6	5
32	Clinically Significant? Depends on Whom You Ask. <i>American Journal of Bioethics</i> , 2012, 12, 18-20.	0.9	4
33	A Randomized Trial of Rapamycin to Increase Longevity and Healthspan in Companion Animals: Navigating the Boundary Between Protections for Animal Research and Human Subjects Research. <i>American Journal of Bioethics</i> , 2018, 18, 58-59.	0.9	4
34	A Pragmatic Trial of Suicide Risk Assessment and Ambulance Transport Decision Making Among Emergency Medical Services Providers: Implications for Patient Consent. <i>American Journal of Bioethics</i> , 2019, 19, 97-98.	0.9	4
35	A Cluster Randomized Trial to Screen for Abusive Head Trauma in the Pediatric Intensive Care Unit—How to Manage Site-Specific Evidence of Racial/Ethnic Disparity. <i>American Journal of Bioethics</i> , 2019, 19, 108-109.	0.9	4
36	Conflicts of Interest and Recommendations for Clinical Treatments That Benefit Researchers. <i>American Journal of Bioethics</i> , 2020, 20, 90-91.	0.9	4

#	ARTICLE	IF	CITATIONS
37	Greater Than Minimal Risk, No Direct Benefit – Bridging Drug Trials and Novel Therapy in Pediatric Populations. <i>American Journal of Bioethics</i> , 2020, 20, 102-103.	0.9	4
38	Ethical Drug Development for Rare Childhood Diseases: When There Are Limited But Promising Data in Adults, How to Choose Between Safety or Efficacy Studies?. <i>American Journal of Bioethics</i> , 2020, 20, 111-113.	0.9	4
39	Bringing Known Drugs to Pediatric Research: Safety, Efficacy, and the Ambiguous Minor Increase in Minimal Risk. <i>American Journal of Bioethics</i> , 2020, 20, 106-108.	0.9	4
40	Conjoined Consent: Informed Consent When Donor and Recipient Are Both Research Participants. <i>American Journal of Bioethics</i> , 2021, 21, 106-107.	0.9	4
41	Informed Consent Conversations: Neither the Beginning nor the End. <i>American Journal of Bioethics</i> , 2021, 21, 76-78.	0.9	4
42	Can Parents Refuse a Potentially Lifesaving Transplant for Severe Combined Immunodeficiency?. <i>Pediatrics</i> , 2016, 138, .	2.1	3
43	A quality improvement project to improve pediatric medical provider sleep and communication during night shifts. <i>International Journal for Quality in Health Care</i> , 2019, 31, 633-638.	1.8	3
44	The Need for Improved Access to Mental Health Services for Youth With Medically Unexplained Symptoms. <i>American Journal of Bioethics</i> , 2018, 18, 29-31.	0.9	3
45	Should Research Participants Be Notified About Results of Currently Unknown but Potential Significance?. <i>American Journal of Bioethics</i> , 2019, 19, 73-74.	0.9	3
46	Germline Gene Editing for Sickle Cell Disease. <i>American Journal of Bioethics</i> , 2020, 20, 46-49.	0.9	3
47	<a href="#">Click Here to Complete This Survey: Online Research, Adolescents, and Parental Consent</a> . <i>American Journal of Bioethics</i> , 2020, 20, 82-83.	0.9	3
48	Supporting Investigators in Challenging Cases: Unease in the Face of an Ethically Appropriate Action. <i>American Journal of Bioethics</i> , 2021, 21, 98-99.	0.9	3
49	When Professional Meets Personal: How Should Research Staff Advertise on Social Media for Research Opportunities?. <i>American Journal of Bioethics</i> , 2021, 21, 38-39.	0.9	3
50	Pediatric Palliative Oncology Patients: Demographics, Treatment and End-of-Life Experiences of a Vulnerable and Understudied Population (TH340D). <i>Journal of Pain and Symptom Management</i> , 2018, 55, 580-581.	1.2	2
51	Clearing Muddy Waters: The Need to Reconceptualize Minor Increase over Minimal Risk in Pediatric Rare Disease Research. <i>American Journal of Bioethics</i> , 2020, 20, 8-10.	0.9	2
52	Opioid Management in the Dying Child With Addiction. <i>Pediatrics</i> , 2021, 147, e2020046219.	2.1	2
53	Minimally Conscious Assumptions and Dangerous Decision-Making Inferences. <i>AJOB Neuroscience</i> , 2013, 4, 61-63.	1.1	1
54	Allocation of Drugs in Short Supply. <i>AMA Journal of Ethics</i> , 2013, 15, 645-648.	0.7	1

#	ARTICLE	IF	CITATIONS
55	International Child Health Competencies. JAMA Pediatrics, 2015, 169, 621.	6.2	1
56	Navigating Nondisclosure Requests in Pediatrics. JAMA Pediatrics, 2017, 171, 1044.	6.2	1
57	Integrating Mental Health Care for Medically Complex Children. Pediatrics, 2020, 146, .	2.1	1
58	Supporting Community-Academic Research Partnerships: Reflections from the Ground. American Journal of Bioethics, 2021, 21, 44-45.	0.9	1
59	The Work of ASBH's Clinical Ethics Consultation Affairs Committee: Development Processes Behind Our Educational Materials. Journal of Clinical Ethics, 2018, 29, 150-7.	0.3	1
60	Enrolling Adolescents with Rare Disease for Early Phase Clinical Trials While Under the Care of Child Protection Services: Balancing Protection and Access. American Journal of Bioethics, 2022, 22, 81-82.	0.9	1
61	Time for a Reboot: Multimodal approaches to improving informed consent communication in pediatric oncology. Pediatric Blood and Cancer, 2022, 69, .	1.5	1
62	Ogilvie Syndrome in a Child With Incurable Malignancy (779). Journal of Pain and Symptom Management, 2012, 43, 467-468.	1.2	0
63	Response to the Letter to the Editor from Bleyer. Journal of Adolescent and Young Adult Oncology, 2015, 4, 93-93.	1.3	0
64	What Are the Limits of Parental Authority? Pediatric Bioethics and the Law (SA531). Journal of Pain and Symptom Management, 2016, 51, 401.	1.2	0
65	“œœ™ve Got This Difficult Case”   “œœ™ Ethics Facilitation and Documentation in Pediatrics (P15). Journal of Pain and Symptom Management, 2016, 51, 312-313.	1.2	0
66	Loss and Bereavement in Adolescent and Young Adult Oncology Patients (S740). Journal of Pain and Symptom Management, 2016, 51, 428-429.	1.2	0
67	When to Say When: Helping the Team and Family Recognize when Death is Inevitable After Pediatric Bone Marrow Transplant (TH356). Journal of Pain and Symptom Management, 2016, 51, 338.	1.2	0
68	An Extravagant Gift From a Grateful Patient. Pediatrics, 2018, 141, .	2.1	0
69	Ethical Considerations for Unblinding a Participant’s Assignment to Interpret a Resolved Adverse Event. American Journal of Bioethics, 2018, 18, 66-67.	0.9	0
70	Autologous Hematopoietic Cell Transplantation without Transfusion in a Teenage Jehovah's Witness: A Case Report from a Pediatric Transplant Center. Biology of Blood and Marrow Transplantation, 2020, 26, S137.	2.0	0
71	Reducing Time to Discharge after Chemotherapy by Standardizing Workflow and Providing Outpatient Intravenous Hydration. Pediatric Quality & Safety, 2021, 6, e415.	0.8	0
72	Abstract 642: Genomes for Kids: Comprehensive DNA and RNA sequencing defining the scope of actionable mutations in pediatric cancer. , 2021, , .		0